First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action

W. Verborg, H. Thomas, D. Bissett, J. Waterfall, J. Steiner, M. Cooper, E. M. Rankin

    Research output: Contribution to journalArticlepeer-review

    15 Citations (Scopus)


    The bis-phenazine XR5944.14 is a novel cytotoxic agent which intercalates into DNA and inhibits transcription. The objectives of this study were to determine the dose-limiting toxicity (DLT), the maximum tolerated dose (MTD) and to describe the pharmacokinetics (PKs) of XR5944.14 when given at doses ranging from 3.6 to 36 mg m(-2) every 3 weeks to patients with advanced tumours. Twenty-seven patients were treated with a total of 77 cycles. Dose-limiting toxicities occurred at doses > or =24 mg m(-2). Oral mucositis was the most common DLT. Two patients developed acute renal failure possibly related to the study drug. Other less-severe toxicities were diarrhoea, nausea, vomiting and fatigue. Haematological toxicity was mild. One patient showed an objective partial response. Pharmacokinetic analysis was performed during the first cycle of treatment and plasma was assayed for XR5944.14 using a validated liquid chromatography tandem mass spectrometry. The systemic exposure of XR5944.14 increased more than proportionally with increasing dose, with inter-patient variability increasing from dose level 24 mg m(-2) onwards. The lack of correlation between toxicity and PK values makes it difficult to recommend a dose for further study in phase 2 trials. More work is needed to explain the inter- and intra-individual variation in PKs and pharmacodynamics.
    Original languageEnglish
    Pages (from-to)844-850
    Number of pages7
    JournalBritish Journal of Cancer
    Issue number7
    Publication statusPublished - Oct 2007


    • Adult
    • Aged
    • Area Under Curve
    • Female
    • Humans
    • Infusions, Intravenous
    • Male
    • Maximum Tolerated Dose
    • Middle Aged
    • Neoplasms
    • Phenazines


    Dive into the research topics of 'First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action'. Together they form a unique fingerprint.

    Cite this